hrp0086p1-p613 | Growth P1 | ESPE2016

Glucose Dysregulation in Children with Growth Hormone Deficiency (GHD), Turner Syndrome (TS) or Born Small for Gestational Age (SGA) Treated with GH: A Report from the NordiNet International Outcome Study (IOS)

Kotnik Primoz , Rohrer Tilman , Pedersen Birgitte Tonnes , Pournara Effie , Christesen Henrik

Background: The prevalence of glucose dysregulation in children treated with GH is not well established.Objective and hypotheses: To evaluate the prevalence of glucose dysregulation in children with growth disorders (GH deficiency (GHD), Turner syndrome (TS), small for gestational age (SGA)) treated with GH (Norditropin, Novo Nordisk) enrolled in NordiNet International Outcome Study (IOS) (NCT00960128), a non-interventional study evaluating safety and ef...

hrp0086p1-p801 | Syndromes: Mechanisms and Management P1 | ESPE2016

Prepubertal Ultra-low-dose Estrogen Therapy is Associated with Better Lipid Profile than Conventional Estrogen Replacement for Pubertal Induction in Adolescent Girls with Turner Syndrome – Preliminary results

Wojcik Malgorzata , Ruszala Anna , Zygmunt-Gorska Agata , Janus Dominika , Wojtys Joanna , Starzyk Jerzy B.

Background: Estrogen replacement is a treatment of choice for pubertal induction in adolescent girls with ovarian failure due to Turner syndrome (TS). Recently published data show, that prepubertal low dose estrogen replacement is more physiologic, and can optimize response to growth hormone treatment, pubertal timing, and improve cognition. The metabolic effects of such treatment regimen have not been fully investigated to date.Objective and hypotheses:...

hrp0082p2-d2-423 | Growth Hormone (1) | ESPE2014

Normal Onset of Clinical Puberty for Age in GH-Treated Children with Noonan Syndrome or Turner Syndrome: Data from the NordiNet® IOS and ANSWER® Program

Ross Judith , Christesen Henrik , Lee Peter , Germak John , Pedersen Birgitte Tonnes , Kotnik Primoz

Introduction: Noonan syndrome (NS) and Turner syndrome (TS) are distinct genetic disorders with similarities in phenotype, including short stature. The NordiNet® IOS and the ANSWER Program® are observational studies evaluating effectiveness and safety of GH treatment in real-world practice.Methods: The study population included children with NS or TS with puberty recordings, enrolled in NordiNet® IOS or ANS...

hrp0089p1-p162 | Growth & Syndromes P1 | ESPE2018

Comparing the Cumulative Dose of Growth Hormone Therapy Using Body Weight-Based Dosing Versus Body Surface Area-Based Dosing in Children with Turner Syndrome – Data from the ANSWER Study

Backeljauw Philippe , Geffner Mitchell , Ross Judith , Holot Natalia , Ostrow Vlady

Background and Objective: The American Norditropin Studies: Web-Enabled Research (ANSWER) Program is a long-term, US-based, non-interventional study designed to collect information on the effectiveness and safety of Norditropin® growth hormone (GH). From June 2002 to September 2016, 20,204 pediatric patients were enrolled by their treating physicians, including 1,003 patients with Turner syndrome (TS). This analysis compares cumulative GH doses when adjusting G...

hrp0089p1-p163 | Growth & Syndromes P1 | ESPE2018

The Association between Growth Hormone Dose and Short-Term Height Outcomes in a Large Cohort of Paediatric Patients with Turner Syndrome: Real-World Data from the NordiNet® International Outcome Study (IOS) and ANSWER Program

Blair Jo , Rohrer Tilman R. , Tonnes Pedersen Birgitte , Roehrich Sebastian , Backeljauw Philippe

Objectives: The recently updated clinical practice guidelines for Turner syndrome (TS) recommend a growth hormone (GH) dose of 45–50 μg/kg/day, increasing to 68 μg/kg/day in case adult height potential is substantially compromised (1). Real-world data on the modifiable factors impacting near-adult height in GH-treated TS patients are limited, but short-term responsiveness to GH has been suggested as one factor (2). We, therefore, analysed the impact of GH dose o...

hrp0086wg3.4 | ESPE Turner Syndrome Working Group (TS) | ESPE2016

Face Perception in Turner Syndrome (TS)

Gepstein Vardit

Individuals with TS exhibit a distinct cognitive profile. They show deficits in visual-spatial and visual-motor skills, such as mental rotation, object assembly, design copying, visual memory and attention, deficits in arithmetic abilities, executive function, and some language aspects, such as verbal fluency. Other intellectual capacities, however, are preserved in TS, and in some domains, such as linguistic receptive and expressive abilities, performance is, at times, even s...

hrp0092p3-155 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Turners Syndrome - Clinical Presentation, Genetics, Investigation and Management: A 10-Year Review

Elechi Hassan Abdullahi , Law James , Alexander Jacqui , Denvir Loiuse , Randell Tabitha , Sachdev Pooja

Background: Turner syndrome (TS) is characterised by a wide phenotype and age at presentation. We reviewed our over-12s Turner clinic over a period of 10 years to evaluate pattern of diagnosis, co-morbidities and management.Subjects & Method: Retrospective data analysis of patients with TS who attended the over-12s clinic (2008-2017, n=28). Data is median (IQR) or mean±SD as appropriate.<p class...

hrp0095p2-129 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Molecular pathways linking fetal growth restriction to cardiometabolic risk in childhood

Perchard Reena , Higgins Lucy , Garner Terence , Stevens Adam , Johnstone Edward , Clayton Peter

Background: Cardiometabolic (CM) risk is linked to being small for gestational age (SGA, birthweight <-2SDS). Fetal growth restriction (FGR) may not result in SGA. We focused on potential CM risk in children born following pregnancies at higher risk for FGR.Aims: To identify associations between fetal and childhood weight trajectory quartiles and CM risk markers. 2.To define molecular pathways potentially associated w...

hrp0092p1-426 | Thyroid (2) | ESPE2019

A Rare Case of Familial Heterozygous Thyroid Hormone Receptor Beta (THRB) Mutation Presenting with Dilated Cardiomyopathy

Hastings Lucy , Saraff Vrinda , Chikermane Ashish , Boelaert Kristien , Lyons Greta , Moran Carla , Mohamed Zainaba

Background: Resistance to thyroid hormone beta (THRβ) is a clinical spectrum which varies in presentation even between individuals with the same mutation. Life-threatening cardiac dysfunction is recognized in homozygous THRβ state but never reported in cases of inherited heterozygous THRβ defects.Aim: We report the first case of familial inherited heterozygous (THRB) beta mutation presenting with ...

hrp0084lbp-1266 | Late Breaking Posters | ESPE2015

Determining the Effects of Race, Skin Colour, and Genotype on the Response to Vitamin D Therapy

Kothandapani Jaya Sujatha Gopal , Evans Lucy , Walsh Jennifer , Eastell Richard , Bishop Nick

Background: Over-dosing and under-dosing of vitamin D in children and young people appears to be common, based on our audit of current practice. The contribution of ethnicity, skin colour, and vitamin D binding protein (VDBP) genotype has not been fully explored during vitamin D treatment.Objective: To investigate how ethnicity/skin colour and genetic variation affect the response to 150 000 units of vitamin D administered to young adults of White Caucas...